Genmab locked in J&J royalty payments dispute

Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Conformis launches implant lawsuit against J&J subsidiary

4 May 2021 US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents.

Americas

J&J announces $6.5bn Momenta acquisition, days after Sanofi deal

20 August 2020 Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.

Big Pharma

J&J, HHS sign expanded deal to find COVID-19 vaccine

14 February 2020 Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Genmab locked in J&J royalty payments dispute

More on this story

Editor's picks

Editor's picks

More features